A
AKBA
Akebia Therapeutics, Inc. Common Stock
$0.70
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Akebia Therapeutics, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$0.11
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.04
Oct 29
Posts
No posts about AKBA yet.
About Akebia Therapeutics, Inc. Common Stock
Akebia Therapeutics is a US biotechnology company that develops and sells medicines for kidney disease. Its main product is Vafseo, a daily pill that treats anemia (a shortage of red blood cells that causes fatigue) in people with long-term kidney disease on dialysis. It earns money by selling Vafseo and a kidney drug called Auryxia, and it is working to expand its pipeline.